Table 1 Characteristics of patients with and without angiotensin receptor blockers therapy
ARB use | No ARB use | P-value | |
|---|---|---|---|
Age (year) | 50.52 ± 11.17 | 51.45 ± 10.01 | 0.682 |
Sex (men/women) | 21/14 | 44/24 | 0.771 |
Weight (kg) | 72.47 ± 16.29 | 77.86 ± 15.77 | 0.110 |
Height (cm) | 167.81 ± 11.70 | 168.30 ± 9.56 | 0.826 |
BMI (kg/m2) | 25.62 ± 5.12 | 27.55 ± 6.15 | 0.119 |
PTDM | 20 | 35 | 0.368 |
Hyperlipidemia | 22 | 36 | 0.179 |
AST (IU/L) | 23.12 ± 9.79 | 26.58 ± 12.80 | 0.183 |
ALT (IU/L) | 29.15 ± 20.65 | 32.60 ± 20.58 | 0.443 |
ALK. Ph (IU/L) | 221.84 ± 94.82 | 258.32 ± 121.92 | 0.142 |
T. Bilirubin (mg/dL) | 0.98 ± 0.50 | 0.95 ± 0.49 | 0.807 |
FBS (mg/dL) | 126.91 ± 54.98 | 141.96 ± 74.00 | 0.301 |
TG (mg/dL) | 190.72 ± 118.59 | 207.88 ± 130.49 | 0.530 |
Cholesterol (mg/dL) | 188.93 ± 52.64 | 186.84 ± 63.45 | 0.871 |
HDL (mg/dL) | 46.09 ± 12.86 | 41.93 ± 14.12 | 0.162 |
LDL (mg/dL) | 103.15 ± 36.36 | 98.61 ± 38.99 | 0.581 |
Hepatic steatosis | 11 | 43 | 0.003 |